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Innate lymphoid cells (ILCs) are emerging as important components of our immune system that have critical 
effector and regulatory functions in both innate and adaptive immune responses. They are enriched at mucosal 
surfaces, such as lung and intestine. Our previous work has shown that 
Lineage-CRTH2-CD45+NKp44-CD117-CD127+ILC1s accumulated in the inflamed terminal ileum of patients 
with Crohn’s disease (CD) at the expense of NKp44+ILC3s. This phenotype conversion impairs the intestinal 
barrier integrity and contributes to the dysregulated immune responses of CD patients. Our next step was to 
search for pathways to modulate this phenotype switch. The aryl hydrocarbon receptor (AHR) is a 
ligand-dependent transcription factor. Initial studies of AHR concentrated on its role in the detoxification of 
xenobiotics. However, recent research has focused on the immune system. Especially, AHR pathway is proven to 
be essential for the maintenance of intestinal ILC3s in mouse models. We examined whether AHR pathway 
participated in the human intestinal ILC phenotype change in the inflamed terminal ileum of CD patients. As 
anticipated, NKp44+ILC3s, NKp44-ILC3s and ILC1s had differential AHR expression. This AHR signaling 
mediated CD117 expression on the surface of ILC3s. The conversion from ILC3 to ILC1 was accompanied by 
the downregulation of AHR expression. We further observed that there was a disparity between AHR protein 
expression and mRNA expression in the inflamed terminal ileum tissues of CD patients compared to unaffected 
areas. These findings suggest that AHR pathway is also important for human intestinal ILC phenotype 
regulation and impaired AHR signaling in the inflamed gut of CD patients possibly contributes to the 
ILC3/ILC1 conversion. 
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CD is a chronic inflammatory condition of the 
gastrointestinal tract and may affect any part from the mouth 
to the anus. The exact cause of CD remains unknown. It has 
been suggested that an abnormal immune response against 
the microorganisms within the gut is responsible for the 
disease in genetically susceptible individuals [1, 2]. Recently, a 
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rapid and exciting expansion in our knowledge of the 
mucosal immunity has occurred. An example is the 
identification of new cell types, such as ILCs. 
ILCs are the first line of defense in our immune system to 
respond to danger signals from the environment by rapidly 
secreting cytokines and chemokines. They are categorized 
into three groups: ILC1, ILC2 and ILC3 according to their 
cytokines production and transcription factors profile [3-6]. In 
mice, ILC3s play a crucial role in gut immunity, by directly 
inducing epithelial cell proliferation and glycosylation, 
promoting anti-microbial peptides production, preventing 
dissemination of commensal bacteria, and limiting 
commensal bacteria specific CD4+ T cell response [7-11]. In 
human, NKp44+ILC3s have been shown to be the major ILC 
subset in the intestine at the steady state [12]. In the context of 
CD, our group and other groups have shown that there were 
significant changes regarding ILCs composition in the 
inflamed gut. NKp44+ILC3s were found to be significantly 
reduced while IFN-γ-producing ILC1s accumulated in the 
inflamed intestinal mucosa of CD patients compared to 
non-inflamed areas [13-20]. This phenotype alteration switches 
ILCs’ role from protective to pathogenic in the maintenance 
of human intestinal immune homeostasis. 
AHR belongs to the family of basic 
helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) proteins. It is a 
ligand-dependent transcription factor located in the 
cytoplasm of cells that upon ligand binding translocates to 
the nucleus, dimerizes with its nuclear translocator (ARNT), 
and binds to AHR response elements in the promoter regions 
of its target genes to initiate their transcription [21-23]. Initial 
studies of AHR focused on its role in mediating toxicity of 
dioxin-like chemicals. Actually, AHR exerts multiple 
functions in our body, acting as an essential sensor for 
environmental factors and human lifestyle factors, such as 
diet, smoking and psychological stress changes. It is a link 
between environment and immunity [24-26].  
Recently, accumulating evidence has indicated that AHR 
signaling is involved in the regulation of differentiation, 
maintenance and function of various mucosal immune cell 
subsets in mouse models, including Th17 cells, Treg cells and 
natural killer cells [27-30]. Also, AHR pathway is necessary for 
the maintenance and function of IL-22-producing ILC3s in 
the gut. AHR knock-out mice have significantly reduced 
numbers of IL-22-producing ILC3s subset in the gut, lack of 
lymphoid tissues cryptopatches and isolated lymphoid 
follicles and less IL-22 production [31-33]. Interestingly, AHR 
expression has been shown to be down-regulated in the 
inflamed mucosa of CD patients [34, 35]. However, the 
association between AHR expression and ILC3s population 
in the human gastrointestinal tract remains unclear.  
Based on all these information, we hypothesized that 
NKp44+ILC3s subset played a protective role in the 
pathogenesis of CD and AHR signaling was essential for the 
maintenance of this subset in the intestinal mucosal lamina 
propria of CD patients. We found that the three intestinal 
ILC subsets (NKp44+ILC3, NKp44-ILC3 and ILC1) had 
differential AHR expression levels. AHR expression in the 
NKp44+ILC3s was the highest while its expression in the 
NKp44-ILC3s was intermediate. ILC1s did not express AHR 
at all. This means that during the ILC3/ILC1 conversion 
process, the AHR expression in the NKp44+ILC3s needs to 
be downregulated. Our data proved that the AHR expression 
was down-regulated in the inflamed NKp44+ILC3s compared 
to ILC3s from unaffected tissues. Also, we noticed that there 
was a disparity between AHR protein expression and mRNA 
expression in the inflamed terminal ileum of our CD patients. 
AHR protein expression was downregulated while its mRNA 
expression was upregulated. It is likely that AHR expression 
in the inflamed gut of CD patients is regulated by a 
post-transcriptional mechanism. This is consistent with a 
recent study which suggests that MicroRNA-124 targets 
AHR in CD to promote intestinal inflammation [35]. 
The impaired AHR signaling pathway causes the 
NKp44+ILC3s phenotypic instability in the inflamed gut of 
CD patients. The potential mechanism probably involves the 
stable expression of surface marker CD117 which is essential 
for ILCs phenotype [36]. In mouse models, one group 
demonstrates that intestinal ILC3s of their AHR knock-out 
mice model has significantly reduced expression CD117 [31]. 
Their chromatin immunoprecipitation (ChIP) study further 
suggests that two canonical AHR binding elements are 
located in the promoter of CD117 gene [31]. In addition, 
another two groups have shown that CD117 is under the 
direct transcriptional control of AHR [37, 38]. For human 
innate lymphoid cells, AHR pathway can regulate their 
CD117 expression as well [39, 40]. We also observed that 
CD117 expression was downregulated in the inflamed 
NKp44+ILC3s. This AHR mediated CD117 expression 
contributes to the maintenance of NKp44+ILC3s phenotype 
in the human gut.  
In summary, our findings suggest that impaired AHR 
signaling involves in the human intestinal ILC3/ILC1 
conversion in the inflamed terminal ileum of CD patients and 
could be a new target of immunotherapy for those patients. 
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